These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 21559417)

  • 1. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.
    Masliah E; Rockenstein E; Mante M; Crews L; Spencer B; Adame A; Patrick C; Trejo M; Ubhi K; Rohn TT; Mueller-Steiner S; Seubert P; Barbour R; McConlogue L; Buttini M; Games D; Schenk D
    PLoS One; 2011 Apr; 6(4):e19338. PubMed ID: 21559417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.
    Spencer B; Valera E; Rockenstein E; Overk C; Mante M; Adame A; Zago W; Seubert P; Barbour R; Schenk D; Games D; Rissman RA; Masliah E
    Acta Neuropathol Commun; 2017 Jan; 5(1):7. PubMed ID: 28086964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.
    Games D; Valera E; Spencer B; Rockenstein E; Mante M; Adame A; Patrick C; Ubhi K; Nuber S; Sacayon P; Zago W; Seubert P; Barbour R; Schenk D; Masliah E
    J Neurosci; 2014 Jul; 34(28):9441-54. PubMed ID: 25009275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.
    Mandler M; Valera E; Rockenstein E; Weninger H; Patrick C; Adame A; Santic R; Meindl S; Vigl B; Smrzka O; Schneeberger A; Mattner F; Masliah E
    Acta Neuropathol; 2014; 127(6):861-79. PubMed ID: 24525765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
    Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
    Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.
    Bae EJ; Lee HJ; Rockenstein E; Ho DH; Park EB; Yang NY; Desplats P; Masliah E; Lee SJ
    J Neurosci; 2012 Sep; 32(39):13454-69. PubMed ID: 23015436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.
    El-Agnaf O; Overk C; Rockenstein E; Mante M; Florio J; Adame A; Vaikath N; Majbour N; Lee SJ; Kim C; Masliah E; Rissman RA
    Neurobiol Dis; 2017 Aug; 104():85-96. PubMed ID: 28476636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases.
    Spencer B; Potkar R; Trejo M; Rockenstein E; Patrick C; Gindi R; Adame A; Wyss-Coray T; Masliah E
    J Neurosci; 2009 Oct; 29(43):13578-88. PubMed ID: 19864570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.
    Games D; Seubert P; Rockenstein E; Patrick C; Trejo M; Ubhi K; Ettle B; Ghassemiam M; Barbour R; Schenk D; Nuber S; Masliah E
    Am J Pathol; 2013 Mar; 182(3):940-53. PubMed ID: 23313024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.
    Spencer B; Trinh I; Rockenstein E; Mante M; Florio J; Adame A; El-Agnaf OMA; Kim C; Masliah E; Rissman RA
    Neurobiol Dis; 2019 Jul; 127():163-177. PubMed ID: 30849508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
    Price DL; Rockenstein E; Ubhi K; Phung V; MacLean-Lewis N; Askay D; Cartier A; Spencer B; Patrick C; Desplats P; Ellisman MH; Masliah E
    PLoS One; 2010 Nov; 5(11):e14020. PubMed ID: 21103359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.
    Spencer B; Michael S; Shen J; Kosberg K; Rockenstein E; Patrick C; Adame A; Masliah E
    Mol Ther; 2013 Jan; 21(1):31-41. PubMed ID: 22508489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.
    Crews L; Spencer B; Desplats P; Patrick C; Paulino A; Rockenstein E; Hansen L; Adame A; Galasko D; Masliah E
    PLoS One; 2010 Feb; 5(2):e9313. PubMed ID: 20174468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
    Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
    Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.
    Lim Y; Kehm VM; Lee EB; Soper JH; Li C; Trojanowski JQ; Lee VM
    J Neurosci; 2011 Jul; 31(27):10076-87. PubMed ID: 21734300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.
    Rockenstein E; Ostroff G; Dikengil F; Rus F; Mante M; Florio J; Adame A; Trinh I; Kim C; Overk C; Masliah E; Rissman RA
    J Neurosci; 2018 Jan; 38(4):1000-1014. PubMed ID: 29246926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
    Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
    Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
    Zhou W; Milder JB; Freed CR
    J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
    Masliah E; Rockenstein E; Adame A; Alford M; Crews L; Hashimoto M; Seubert P; Lee M; Goldstein J; Chilcote T; Games D; Schenk D
    Neuron; 2005 Jun; 46(6):857-68. PubMed ID: 15953415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.